

KEY FEATURES (Source: Amundi Group)

Inception date : 10/10/2024

Fund structure : SICAV under Luxembourg law

Directive : UCITS IV

Benchmark :

100% MSCI ACWI IMI ARTIFICIAL INTELLIGENCE
SELECT ISSUER CAPPED NR Close

Currency : EUR

Type of shares : Capitalization

ISIN code : LU2860962120

Bloomberg code : CIAIA2E LX

Minimum recommended investment horizon :
5 years

Risk Indicator (Source : Fund Admin)



Lower Risk

Higher Risk

 The SRI represents the risk and return profile as presented in the Key Information Document (KID). The lowest category does not imply that there is no risk. The SRI is not guaranteed and may change over time. The risk indicator assumes you keep the product for 5 years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

KEY FIGURES (Source: Amundi Group)

Net Asset Value (NAV) : 148.42 (EUR)

Assets Under Management (AUM) :
312.38 (million EUR)

KEY PEOPLE (Source: Amundi Group)

Management company : CPR ASSET MANAGEMENT

Custodian / Administrator :

CACEIS Bank, Luxembourg Branch / CACEIS Fund
Administration Luxembourg

OPERATION & FEES (Source: Amundi Group)

Frequency of NAV calculation : Daily

Order cut-off time : 14:00 CET Luxembourg time

Minimum initial subscription :

1 Ten-Thousandth of Share(s)

Minimum subsequent subscription : Nil

Subscription fee (max) / Redemption fee :
5.00% / 0.00%

**Management fees and other administrative or
operating costs :**
2.16%

Performance fees : No


All details are available in the legal documentation

INVESTMENT STRATEGY (Source: Amundi Group)

The investment objective is to outperform the MSCI ACWI IMI Artificial Intelligence Select Issuer Capped index over a long-term period (minimum of five years) by investing in international equities that contribute to or benefit from the development of artificial intelligence while integrating Environmental, Social and Governance (E, S, and G) criteria in the investment process.

ANALYSIS OF THE NET PERFORMANCE (Source: Fund Admin)

CHANGE IN NET ASSET VALUE BASE 100 (Source: Fund Admin)



ANNUALISED PERFORMANCES (Source: Fund Admin) ¹

	YTD	1 month	3 months	1 year	3 years	5 years	Since
Since	31/12/2025	31/07/2026	29/05/2026	29/08/2025	-	-	10/10/2024
Portfolio	30.20%	2.39%	-3.03%	36.20%	-	-	23.23%
Benchmark	25.96%	3.52%	-3.10%	37.08%	-	-	25.92%
Spread	4.25%	-1.13%	0.07%	-0.88%	-	-	-2.69%

¹ Data corresponding to periods of more than a year are annualised.

Offer to Bid returns *

	YTD	1 month	3 months	1 year	Since
Since	31/12/2025	31/07/2026	29/05/2026	29/08/2025	10/10/2024
Portfolio	24.00%	-2.73%	-7.87%	29.39%	17.36%

* Offer to Bid returns include an assumed sales charge of 5%, which may or may not be charged to investors

ANNUAL PERFORMANCES (Source: Fund Admin) ²

	2025	2024	2023	2022	2021
Portfolio	4.27%	-	-	-	-
Benchmark	12.02%	-	-	-	-
Spread	-7.74%	-	-	-	-

* Performance varies over time and is not a reliable indication of future results. The investments are subject to market fluctuations and may gain or lose value.

RISK ANALYSIS (Source: Fund Admin) *

	1 year	3 years	5 years	Inception to date *
Portfolio Volatility	25.77%	-	-	25.43%
Portfolio Information ratio	0.04	-	-	-0.42
Tracking Error ex-post	6.16%	-	-	5.25%


* Annualised data

EQUITY

31/08/2026


PORTFOLIO BREAKDOWN (Source: Amundi Group)

SECTOR BREAKDOWN (Source: Amundi Group) *




* % of assets

GEOGRAPHICAL BREAKDOWN (Source: Amundi Group)



BREAKDOWN BY CURRENCY (Source: Amundi Group) **



** As a percentage of the assets - including currency hedging

ANALYSIS RATIOS

	Portfolio
Average market Cap (Bn €)	1,248.96
% Mid Caps + Small Caps	8.11
% Large Caps	91.89
Per 12 Month forward	17.84
Price to Book	7.98
Price to Cash Flow	21.43
Dividend Yield (%)	0.47
Annualized EPS Growth (n/n+2) (%)	28.03
Annualized Revenue Growth (n/n+2) (%)	27.31
Issuer number (excluding cash)	61
Cash as % of total assets	0.90%

MAIN POSITIONS IN PORTFOLIO

(Source: Amundi Group) *

	Sector	Weight	Spread / Index
ALPHABET INC CL A	Communication Services	6.10%	3.79%
TAIWAN SEMICONDUCTOR-SP ADR	Information Technology	6.09%	6.09%
BROADCOM INC	Information Technology	5.97%	1.73%
ADVANCED MICRO DEVICES	Information Technology	5.57%	0.22%
AMAZON.COM INC	Consumer Discretionary	5.41%	0.69%
NVIDIA CORP	Information Technology	4.77%	0.06%
MICROSOFT CORP	Information Technology	3.67%	-2.05%
SAMSUNG ELECTRONICS	Information Technology	3.37%	3.37%
ARISTA NETWORKS INC	Information Technology	3.05%	1.47%
ORACLE CORP	Information Technology	2.98%	1.25%

* Excluding mutual funds

MANAGER'S COMMENT

August 2026 was dominated by concerns over long-term interest rates. The deadlock in negotiations between Iran and the United States, against a backdrop of sporadic attacks, maintained oil volatility, with Brent ending the month at \$89. The persistence of energy prices at high levels rekindled inflation fears and weighed on bond markets. In response to the rise in long-term rates, U.S. Treasury Secretary Scott Bessent announced at least a doubling of long-term Treasury buybacks for the quarter.

The inflation figures published in August, relating to the month of July, sent a mixed signal. In the United States, headline inflation (CPI) slowed to 3.4% year-on-year, compared to 3.5% in June, while core inflation fell to 2.5%, its lowest of the year. In the eurozone, by contrast, inflation accelerated to 2.9%, compared to 2.8% in June, driven by a renewed rise in the energy component (+10.3% year-on-year), linked to oil and gas prices. Core inflation there came out at 2.5%.

Business surveys remained generally well oriented despite energy pressures. In the eurozone, the composite PMI rose for the third consecutive month to 52.1 in August, a high since November, supported by German industry. In the United States, the ISM manufacturing index jumped to 55.6 in July, its best level since May 2022, while the ISM services index held steady at 54.1. Conversely, the July employment report disappointed, with 23,000 net non-farm job losses and significant downward revisions, even though the unemployment rate fell to 4.1%, a thirteen-month low, due to a further decline in the participation rate. In Japan, unemployment fell to 2.4% in July, while Tokyo inflation reached a five-month high in August. China remains lagging, with PMIs falling to a four-month low in July, still reflecting the contrast between AI-related segments and the rest of the economy.

No major central bank met in August. The main event was Jackson Hole, where Kevin Warsh was rather reassuring on employment but concerned about the inflation trajectory. For the first time since the start of his term, he indicated that the Fed's attention should now focus primarily on price stability. In the eurozone, ECB minutes suggest that a majority of the Governing Council would be ready to raise rates in September to contain the effects of rising energy prices. In Japan, several BoJ officials called for an acceleration of tightening, with markets now anticipating a strong probability of a 1.25% rate as early as September.

Equity markets held up well to oil volatility, supported by renewed interest in the artificial intelligence theme. The S&P 500 set several new records before ending the month up 2.6%. The Eurostoxx 600 also reached a new all-time high before finishing with a more modest gain (+0.3%). The Nikkei gained 3%, still driven by semiconductors, while the MSCI Emerging rose 3.2%, also supported by technology.

Bond yields generally rose, especially at the end of the month after Kevin Warsh's speech. The U.S. 10-year ended at 4.74%, a high since the start of 2025. The German 10-year rose sharply to 3.30%, its highest level since 2011, amid expectations of an ECB hike, while sovereign spreads in the eurozone widened slightly. In Japan, the 10-year also rose to 2.92% in anticipation of BoJ tightening. Finally, gold rebounded strongly (+9.6% for the month), its best monthly performance since January, supported by interventionist measures from the U.S. Treasury.

The month was marked by a rapid rebound, concentrated in the first half of August after the late July trough. Software was the main driver of the portfolio, accounting for most of the relative performance, with strong gains in ServiceNow, Zscaler, and Snowflake, on the back of reassuring earnings releases and less pronounced fears of potential value destruction in the sector by generative AI. Cybersecurity also rebounded strongly, driven by CrowdStrike and Rubrik. Networking and infrastructure contributed positively via Arista Networks and Lumentum. Underperformance relative to the index is mainly explained by a different allocation than the benchmark, which is more exposed to certain large-cap AI infrastructure stocks, notably Nvidia, as well as the relative weakness of several portfolio semiconductors, particularly KLA. Conversely, stock selection within Communication Services helped limit the extent of underperformance and was generally favorable, with Netflix as a strong contributor. The rebound was also amplified by the unwinding of hedge fund positions, notably after the Situational Awareness episode.

Management continued to take profits on the stocks that had rebounded the most, particularly in the software segment, in order to reduce momentum and concentration. At the same time, the fund strengthened or initiated positions deemed more asymmetric, with Samsung Electronics and by tactically increasing exposure to certain AI adopters.

The fund remains constructive on the AI-related investment cycle, but with a more selective approach after the rebound. Management favors segments where fundamental visibility remains strongest, such as critical software, cybersecurity, network infrastructure, and certain memory pockets, while remaining disciplined on valuations and entry points.

Important and Legal Information

This document contains information about CPR Invest - Artificial Intelligence (the "Fund"), a sub-fund of CPR Invest, an undertaking for collective investment in transferable securities existing under Part I of the Luxembourg law of 17 December 2010, organised as a société anonyme and qualifies as a société d'investissement à capital variable (SICAV) registered with the Luxembourg Trade and Companies Register under number B-189.795 and having its registered office at 5, allée Scheffer, L-2520 Luxembourg. The management company of the Fund is CPR Asset Management – 91-93, Boulevard Pasteur 75015 Paris - France and the Singapore Representative of the Fund is Amundi Singapore Limited (Registration No. 198900774E), 80 Raffles Place, UOB Plaza 1, #37-01A, Singapore 048624 (CPR Asset Management and/or its affiliated companies, including without limitation Amundi Singapore Limited, being hereinafter referred to individually or jointly as "Amundi"). Amundi Singapore Limited is regulated by the Monetary Authority of Singapore.

This is a marketing communication. Investors should read the Singapore Prospectus and the Product Highlights Sheet before deciding to invest in the Fund. The share classes of the Fund available for offer to the retail public in Singapore are set out in the Singapore Prospectus and the Product Highlights Sheet, which together with the latest annual and semi-annual reports (if any) may be obtained, free of charge, at the registered office of the Singapore Representative of the Fund or at www.amundi.com.sg or the Fund's authorised distributors.

This document is for information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell the Fund in any jurisdiction where such offer, solicitation or invitation would be unlawful. This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in the United States or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any U.S. Person (as this term is defined in SEC Regulation S under the U.S. Securities Act of 1933 and in the Singapore Prospectus of the Fund). The Fund is not registered in the United States under the Investment Company Act of 1940 and shares of the Fund are not registered in the United States under the Securities Act of 1933. Accordingly, this document is for distribution or to be used solely in jurisdictions where it is permitted and to persons who may receive it without breaching applicable legal or regulatory requirements, or that would require the registration of Amundi or its affiliates in these countries.

Past performance and any forecasts made are not indicative of future performance of the Fund.

Please note that distribution/dividends (if applicable) are not guaranteed unless otherwise stated in the dividend policy for the relevant share class contained in the Singapore Prospectus. Investors should review the relevant dividends disclosure report (if applicable) found on www.amundi.com.sg. Any opinion or view presented is subject to change without notice. The information in this document is intended for general circulation without taking into account the specific investment objectives, financial situation or particular needs of any particular investor. An investor may wish to seek advice from a financial adviser regarding the suitability of the Fund, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before making a commitment to purchase shares in the Fund.

The Fund may invest in Additional Tier 1 and/or Tier 2 capital instruments issued by banks and insurers incorporated in Singapore, which have loss absorption features and include terms which may result in such instruments being, inter alia, partly or wholly written off, written down and/or converted to ordinary shares of the issuer upon the occurrence of a pre-defined trigger event. Trigger events are complex and difficult to predict, may be outside of the issuer's control (for example, due to regulatory action) and can result in a significant or total reduction in the value of such instruments, thereby giving rise to loss suffered by the Fund. Investors should not purchase the shares / units of the Fund if they do not understand the nature of an investment in Additional Tier 1 and/or Tier 2 capital instruments or are not comfortable with the accompanying risks. Retail investors who do not have the knowledge or experience of investing in such sophisticated products are encouraged to seek advice from a professional financial adviser. Investors should determine the suitability of an investment in the Fund in light of their own circumstances, and in particular the risk that their lack of relevant knowledge and expertise may cause them to lose all or a significant portion of the amount invested.

Where applicable and contemplated in the Singapore Prospectus, the Fund may invest in financial derivatives as part of its strategy, and a material portion of the returns may be generated from financial derivative strategies. In such scenarios, the Fund will be subject to risks associated with such investments as further detailed in the Singapore Prospectus. Additional risk factors are described in the Singapore Prospectus. Investments in the Fund are subject to investment risks, including the possible loss of the principal amount invested. Such activities may not be suitable for everyone. Value of the shares in the Fund and the income accruing to the shares, if any, may fall or rise. Any forecast, projection or target is indicative only and is not guaranteed in any way. Such information is solely indicative and may be subject to modification from time to time. References to specific securities are presented to illustrate the application of our investment philosophy only and are not to be considered recommendation by Amundi.

It is the responsibility of investors to read the legal documents in force in particular the current Singapore prospectus of the Fund. Subscriptions in the Fund will only be accepted on the basis of their latest prospectus available in English and/or the Product Highlights Sheet. A summary of information about investors' rights and collective redress mechanisms can be found in English on the regulatory page at <https://about.amundi.com/Metanav-Footer/Footer/Quick-Links/Legal-documentation>.

Information on sustainability-related aspects (if applicable) can be found at <https://about.amundi.com/Metanav-Footer/Footer/Quick-Links/Legal-documentation>.

The information contained in this document is as at the date of publication of this document except where otherwise stated. The information contained in this document has been obtained from sources believed to be reliable but has not been independently verified, although Amundi and its affiliated companies believe it to be fair and not misleading. Total percentage may not add to 100% due to rounding. Amundi does not accept any liability whatsoever whether direct or indirect that may arise from the use of information contained in this document. Amundi and its associates, directors, connected parties and/or employees may from time to time have interests and/or underwriting commitments in the investments mentioned in this document. Amundi does not guarantee that all risks associated to the transactions mentioned herein have been identified, nor does it provide advice as to whether you should enter into any such transaction. Amundi does not make any representation as to the merits, suitability, expected success, or profitability of any such transaction mentioned herein.

Pursuant to the new Guidelines on marketing communications under Regulation (EU) 2019/1156 of 20 June 2019 on cross-border distribution of funds issued by the European Securities and Markets Authority (ESMA), performance returns which are less than 12 months will not be reported for European domiciled funds.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

The information contained shall not be copied, reproduced, modified, translated or distributed without the prior written approval of Amundi.